Last updated: February 19, 2026
Neulasta (pegfilgrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia, a condition characterized by a low count of neutrophils, in patients undergoing chemotherapy. This analysis examines Neulasta's market dynamics, including its patent status, competitive landscape, and historical financial performance, to inform R&D and investment decisions.
What is Neulasta and its Therapeutic Role?
Neulasta is a recombinant DNA-derived protein produced in E. coli using a proprietary yeast fermentation process. It is a pegylated form of filgrastim, a G-CSF that stimulates the production, maturation, and activation of neutrophils. This action is critical in mitigating chemotherapy-induced neutropenia (CIN), a common and potentially life-threatening side effect that can lead to febrile neutropenia and dose reductions or delays in cancer treatment. By reducing the incidence, duration, and severity of neutropenia, Neulasta aims to maintain the intended dose intensity of chemotherapy, thereby improving treatment outcomes [1].
The drug is administered via subcutaneous injection, with a single dose typically given once per chemotherapy cycle. This extended duration of action, compared to the shorter-acting filgrastim (Neupogen), offers a significant convenience advantage for patients and healthcare providers [2].
What is Neulasta's Patent and Exclusivity Status?
Neulasta's market exclusivity has been significantly influenced by patent expiries and the subsequent emergence of biosimil products.
Key Patents and Expiry Dates
- U.S. Patent No. 5,581,470: This patent, covering pegylated G-CSF, was a foundational patent for Neulasta. It was originally set to expire in 2015.
- U.S. Patent No. 6,025,320: This patent, also related to pegylated G-CSF, expired around the same time.
- Other Related Patents: Amgen, the originator, held numerous other patents covering manufacturing processes, formulations, and methods of use. However, the core patents protecting the active molecule and its pegylated form were the primary drivers of early exclusivity.
The expiry of these key patents opened the door for biosimilar development. The U.S. Patent and Trademark Office (USPTO) and various court decisions played a crucial role in defining the timeline for market entry of biosimil competitors [3].
Biosimilar Entry and Market Impact
The first biosimilar to Neulasta in the United States, Udenyca (pegfilgrastim-cbqv) from Coherus BioSciences, received FDA approval in September 2018 and launched in January 2019. This marked the beginning of significant price erosion and market share redistribution [4].
Subsequent biosimilar approvals and launches include:
- Ziextenzo (pegfilgrastim-mxes) by Sandoz (Novartis) - Approved in November 2019.
- Fulphila (pegfilgrastim-jmdb) by Biogen (marketed by Samsung Bioepis) - Approved in June 2018.
- Nyvepria (pegfilgrastim-h1b1) by Pfizer - Approved in April 2021.
The entry of multiple biosimil competitors has led to a substantial decrease in Neulasta's average selling price (ASP) and a decline in its market share.
What is the Competitive Landscape for Neulasta?
The competitive landscape for Neulasta has evolved from a monopolistic market to one with significant biosimilar penetration.
Original Product
- Neulasta (pegfilgrastim) by Amgen: As the originator product, Neulasta benefited from market exclusivity for over a decade.
Biosimilar Competitors
The primary competition for Neulasta now comes from FDA-approved biosimil versions. These products are highly similar to Neulasta in terms of safety, efficacy, purity, and potency, as demonstrated through analytical, pharmacokinetic, and pharmacodynamic studies.
Key biosimil competitors include:
- Udenyca (Coherus BioSciences): One of the earliest entrants, Udenyca has captured a notable share of the market.
- Ziextenzo (Sandoz): Sandoz's entry leverages its global experience in biosimilar development and commercialization.
- Fulphila (Biogen/Samsung Bioepis): This collaboration brought another significant biosimilar to market.
- Nyvepria (Pfizer): Pfizer's entry further intensified competition, utilizing its extensive commercial network.
Other Related Therapies
While biosimil pegfilgrastim is the most direct competition, other G-CSF agents and alternative supportive care strategies can be considered indirect competitors. These include:
- Filgrastim (Neupogen): The original, shorter-acting G-CSF. While less convenient, it remains an option, particularly due to lower cost in some settings.
- Sargramostim (GM-CSF): Another G-CSF that stimulates neutrophil production but also affects monocytes and dendritic cells.
- Novel agents: Research continues into novel approaches for managing chemotherapy-induced myelosuppression.
The market dynamics are heavily influenced by pricing strategies, payer formulary decisions, and physician prescribing habits influenced by evidence of clinical interchangeability and cost-effectiveness.
What Has Been Neulasta's Financial Trajectory?
Neulasta was a blockbuster drug for Amgen, generating substantial revenue during its period of market exclusivity. However, its financial trajectory has shifted dramatically with the advent of biosimilar competition.
Peak Revenue Generation
During its peak, Neulasta was one of Amgen's top-selling products.
- 2014: Neulasta reported net sales of approximately $4.7 billion [5].
- 2015: Net sales remained strong, around $4.6 billion.
This period reflects the drug's dominance in the market and its critical role in cancer care protocols.
Impact of Biosimilar Competition on Revenue
The launch of biosimil pegfilgrastim has led to a sharp and sustained decline in Neulasta's sales.
- 2019: Following the U.S. launch of Udenyca, Neulasta's sales began to decline significantly. Amgen reported U.S. net sales of Neulasta decreasing by approximately 15% in the first quarter of 2019 compared to the prior year [6].
- 2020: Global sales continued to drop. For the full year 2020, Neulasta sales were approximately $2.7 billion, a decline of about 25% year-over-year [7].
- 2021: The downward trend persisted. Neulasta generated approximately $1.9 billion in global sales, representing a decline of about 26% from 2020 [8].
- 2022: Global sales for Neulasta were approximately $1.4 billion, a 24% decrease compared to 2021 [9].
- 2023 (Year-to-date as of Q3): Continued sales pressure is evident. For the first nine months of 2023, Neulasta sales were approximately $979 million, a decrease of 20% compared to the same period in 2022 [10].
This revenue trajectory demonstrates the typical impact of biosimilar entry on originator biologic products, characterized by rapid market share loss and significant price erosion.
What Are the Future Market Projections for Neulasta and its Biosimil Class?
The market for pegfilgrastim, both originator and biosimilar, is projected to continue its competitive pricing and market share dynamic.
Biosimilar Market Growth
The global biosimilar market, including pegfilgrastim, is expected to grow at a significant compound annual growth rate (CAGR) over the next decade. This growth is driven by:
- Patent expiries of blockbuster biologics.
- Increasing demand for affordable treatment options.
- Payer and provider adoption of biosimil therapies.
- Expansion of biosimilar development pipelines.
The pegfilgrastim biosimilar segment is a mature category within the biosimilar market, having already experienced the initial wave of competition. Future growth will be characterized by intense price competition among multiple biosimilar manufacturers.
Price Erosion and Market Share Distribution
- Continued Price Compression: Expect ongoing price erosion as additional biosimil competitors may emerge or existing ones expand their market reach. Pricing strategies will become increasingly competitive, driven by tenders, formulary wins, and contract negotiations with payers and hospital systems.
- Market Share Stabilization: While Neulasta's market share will likely continue to decline, the overall pegfilgrastim market (including biosimil and originator) will remain substantial. Biosimil pegfilgrastim products are expected to capture the vast majority of the market.
- Originator Strategy: Amgen's strategy for Neulasta in the face of biosimilar competition often involves optimizing supply chains, exploring new indications (though less likely for a mature product), and focusing on its portfolio of newer, innovative biologics.
Key Factors Influencing Future Dynamics
- Reimbursement Policies: Payer policies regarding biosimilar reimbursement and patient co-pays will remain critical. Favorable policies can accelerate biosimilar uptake.
- Physician Prescribing Patterns: Physician confidence in the clinical equivalence and safety of biosimil pegfilgrastim is paramount. Education and real-world evidence play a role in shaping prescribing habits.
- Manufacturing Capacity and Supply Chain Reliability: The ability of biosimilar manufacturers to ensure consistent supply and quality will influence their market penetration.
- Legal and Regulatory Landscape: Ongoing legal challenges related to patent litigation and biosimilar approval pathways can impact market entry timelines and competitive dynamics.
The market will continue to be driven by cost-effectiveness, with biosimil pegfilgrastim becoming the standard of care for preventing chemotherapy-induced neutropenia due to its significantly lower acquisition cost compared to the originator.
Key Takeaways
- Neulasta (pegfilgrastim) has transitioned from a highly profitable monopoly product for Amgen to a market facing intense competition from multiple biosimil versions.
- Key patents protecting Neulasta have expired, enabling the launch of biosimil competitors, starting with Udenyca in January 2019.
- The market is now characterized by significant price erosion and a redistribution of market share from the originator to biosimilar manufacturers, including Coherus BioSciences, Sandoz, Biogen/Samsung Bioepis, and Pfizer.
- Neulasta's global net sales have declined sharply from peak revenues exceeding $4 billion annually to approximately $1.4 billion in 2022 and are projected to continue decreasing.
- The future market for pegfilgrastim will be dominated by biosimilar competition, with ongoing price compression and market share gains for these lower-cost alternatives.
Frequently Asked Questions
-
What is the primary mechanism of action for Neulasta and its biosimil equivalents?
Neulasta and its biosimilar pegfilgrastim products are recombinant, pegylated forms of granulocyte colony-stimulating factor (G-CSF). They work by stimulating the bone marrow to produce more neutrophils, a type of white blood cell crucial for fighting infection, thereby preventing or reducing the severity of chemotherapy-induced neutropenia [1].
-
When did the first biosimilar to Neulasta receive FDA approval and launch in the U.S. market?
The first biosimilar to Neulasta in the U.S., Udenyca (pegfilgrastim-cbqv) by Coherus BioSciences, received FDA approval in September 2018 and was launched in January 2019 [4].
-
How has the introduction of biosimil pegfilgrastim impacted the average selling price (ASP) of Neulasta?
The introduction of multiple biosimilar competitors has led to significant price erosion. The ASP for Neulasta has decreased substantially as biosimil versions offer lower-cost alternatives, compelling the originator to reduce its pricing to remain competitive to some extent and influencing market dynamics through payer negotiations and formulary positioning.
-
Are there any key differences in clinical efficacy or safety between Neulasta and its approved biosimil versions?
According to the FDA's biosimilar approval pathway, approved biosimil pegfilgrastim products are highly similar to Neulasta, demonstrating no clinically meaningful differences in safety, purity, and potency. The approval process requires analytical, pharmacokinetic, and pharmacodynamic studies, as well as clinical trial data to confirm this high degree of similarity [11].
-
What is Amgen's current market strategy for Neulasta in light of biosimilar competition?
Amgen's strategy for Neulasta in the biosimilar era typically involves defending its market share where possible, optimizing its supply chain, and focusing on its portfolio of newer, innovative products. The company also engages in pricing and contracting strategies to retain some market presence, though significant revenue decline is an expected outcome of biosimilar entry [9].
Citations
[1] Amgen. (n.d.). Neulasta® (pegfilgrastim) Prescribing Information. Retrieved from Amgen website.
[2] Denning, S. M. (2012). Pegfilgrastim: A long-acting granulocyte colony-stimulating factor. The American Journal of Managed Care, 18(1 Suppl), S13-S18.
[3] U.S. Food & Drug Administration. (2019). Biosimilar product information. Retrieved from FDA website.
[4] Coherus BioSciences. (2019, January 8). Coherus BioSciences Announces UDENYCA™ (pegfilgrastim-cbqv) is Commercially Available. [Press Release].
[5] Amgen. (2015, February 4). Amgen Reports Fourth Quarter and Full Year 2014 Results. [Press Release].
[6] Amgen. (2019, April 25). Amgen Reports First Quarter 2019 Results. [Press Release].
[7] Amgen. (2021, February 4). Amgen Reports Fourth Quarter and Full Year 2020 Results. [Press Release].
[8] Amgen. (2022, February 3). Amgen Reports Fourth Quarter and Full Year 2021 Results. [Press Release].
[9] Amgen. (2023, February 2). Amgen Reports Fourth Quarter and Full Year 2022 Results. [Press Release].
[10] Amgen. (2023, October 26). Amgen Reports Third Quarter 2023 Results. [Press Release].
[11] U.S. Food & Drug Administration. (2015). Guidance for Industry: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Retrieved from FDA website.
